| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Merus N.V.$90
-6.86 (-7.08%)
C 45Pipeline Score Overvalued Biotech · Commercial
Market Cap
6.83 B
EPS
-5.33
P/E Ratio
-
Value Trade
252.72 M
SEC Financials
Q3 2025Dilution Risk
40%Revenue
12.15 M
R&D Expenses
80.02 M
Total Assets
904.20 M
Total Liabilities
129.26 M
Equity
774.93 M
D/E Ratio
12,345
-7.12 %
Week
-6.35 %
1 Month
-3.87 %
3 Month
71.33 %
6 Month
418.73 %
5 Year
823.08 %
All Time
Cash Data
Cash Position
635.93 M
Monthly Burn
32.16 M
Runway
11.4 mo
Burn Trend
StableSEC Filing
Oct 31, 2025
Overview
Volume
2.73 M
52 Week Range
33.19 - 97.14
% held by Insiders
10.96 %
% held by Institutions
90.07 %
Enterprise Value
6.20 B
Total Shares
75.63 M
Short %
1.17 %
Float Shares
69.95 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-05-08 | Bizengri (zenocutuzumab-zbco) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-08 | Bizengri (zenocutuzumab-zbco) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-08 | Bizengri (zenocutuzumab-zbco) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C45
Pipeline Score $1.4B
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 65%
Small Cap (rank 320 of 912)
Percentile RankMerus N.V. carries a moderate pipeline score (45/100), with $2.9B risk-adjusted pipeline value, led by Petosemtamab in Head and Neck Squamous Cell Carcinoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petosemtamab Small molecule | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT06525220 | 65% | $1.5B | RECRUITING | 1,300 | VERY_FAST | C (57) | Jul 1, 2030 | - | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
petosemtamab BreakthroughFast Track | metastatic colorectal cancer | Phase 2 | 2025-10-25 | 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd); 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) Read More | Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid Read More | |
petosemtamab BreakthroughFast Track | metastatic colorectal cancer | Phase 2 | 2025-10-25 | 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd); 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) Read More | Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid Read More | |
petosemtamab BreakthroughFast Track | metastatic colorectal cancer | Phase 2 | 2025-10-25 | 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd); 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) Read More | Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRUS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MRUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How MRUS ranks across every disease it competes inCompetitive Position is a premium feature
See how MRUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial